Program
GS-0151
A development code.
Its studies are mostly in Arthritis, Rheumatoid, led by Gilead Sciences.
Furthest: phase 1, since Mar 24, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 11 open or running | phase 1since Mar 24, 2025 | Mar 24, 2025 | Mar 2027phase 1 · NCT06902519 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06902519 · 65 enrolled · United States, Georgia, Germany and more
Ahead
- Mar 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT06902519
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06902519Arthritis, Rheumatoid · United States, Georgia, Germany and more | 1 | Active, not recruiting | Mar 2027 | 65 |
How it is read
Names in the registry
- “GS-0151”, 1 entry
Codes read as this program: GS0151.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.